News & Updates
Filter by Specialty:
Oral ritlecitinib shows promise against nonsegmental vitiligo
The use of ritlecitinib, an oral JAK3/TEC inhibitor, appears effective for the treatment of nonsegmental vitiligo (NSV) and is well-tolerated for over 48 weeks of follow-up, reports a recent study.
Oral ritlecitinib shows promise against nonsegmental vitiligo
17 Nov 2022
Long-term relugolix combo helps with heavy periods, anaemia in women with uterine fibroids
Treatment with relugolix combination for up to 52 weeks yields sustained reductions in heavy menstrual bleeding as well as subsequent increases in iron stores in women with uterine leiomyomas, as shown in a study.
Long-term relugolix combo helps with heavy periods, anaemia in women with uterine fibroids
16 Nov 2022
Adjunctive semaglutide yields additional weight loss in teens with obesity
Once-weekly treatment with semaglutide, when administered with lifestyle intervention, leads to greater reduction in body mass index among adolescents with obesity as compared with lifestyle intervention alone, as shown in the STEP TEENS study.
Adjunctive semaglutide yields additional weight loss in teens with obesity
16 Nov 2022
Intensive BP-lowering a no-go after reperfusion in ischaemic stroke
An intensive blood pressure target (<120 mm Hg) should be avoided in patients who have undergone endovascular thrombectomy for acute ischaemic stroke (AIS) for large-vessel occlusion (LVO), results of the phase III ENCHANTED2/MT* trial showed.
Intensive BP-lowering a no-go after reperfusion in ischaemic stroke
14 Nov 2022
Rezvilutamide-ADT trumps bicalutamide-ADT for high-volume mHSPC
In the interim analyses of the phase III CHART trial, a combination regimen of ADT* and the novel second-generation androgen-receptor (AR) inhibitor rezvilutamide trumped the bicalutamide-ADT combination in terms of survival outcomes in individuals with high-volume metastatic hormone-sensitive prostate cancer (mHSPC).
